SANTA ANA, Calif. (Map) - SANTA ANA, Calif., Jan. 30 /PRNewswire-FirstCall/ -- When it comes to achieving 20/20 vision, no two eyes are alike -- and, as such neither should be your vision correction. Launching nationwide, the iLASIK(TM) procedure is the very first vision correction procedure designed to be 100 percent custom- fit from beginning to end. The iLASIK(TM) procedure addresses the uniqueness of your two eyes -- from the individual curvature of your corneas, to the microscopic nuances of your eye's anatomy -- designed to deliver the exact correction you need to achieve 20/20 or better vision.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO)

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/amo/31658/

"The iLASIK(TM) procedure has been a decade in the making, with each new advancement furthering the next," said

Dr. Kerry Solomon, professor of ophthalmology at the Medical University of South Carolina (MUSC) and an iLASIK(TM) patient. "With this unveiling, we've reached the final frontier. Quite honestly, there is nothing better on the horizon. "The iLASIK(TM) procedure eliminates confusion for patients seeking the very best in laser vision correction surgery."

The iLASIK(TM) brand combines today's leading technologies into one premium procedure. Prior to the iLASIK(TM) procedure, the burden was on the patient to research the best LASIK technologies, compare and contrast the clinical data of the various advancements, and then identify a physician who offered the particular combination of technologies the patient preferred. That is, if they could follow the chain of brands and combination of brands so prevalent in LASIK marketing.

"The iLASIK(TM) brand removes the veil of confusion in LASIK advertising," said Ron Bache, global vice president of marketing for AMO's refractive group. "Patients now can find all of the most advanced laser vision correction technologies available today under the banner of one premium procedure."

Custom-Fitting The iLASIK(TM) Procedure

Just like the tailoring of a fine suit or couture fashion, the iLASIK(TM) procedure is 100 percent tailor-made for the patient, their vision and the unique characteristics of their eyes. Three-dimensional mapping, precise measurement and the use of beginning-to-end, state-of-the-art technologies differentiate the iLASIK(TM) procedure from all others. The iLASIK(TM) procedure also provides better visual outcomes and superior safety through reduced flap complications. The iLASIK(TM) procedure is performed in three steps:

-- Step One: iLASIK(TM) surgeons now have the most precise tools to measure and map the uniqueness of your two eyes -- down to the most microscopic characteristics individual to you. Three-dimensional mapping -- known as a WaveScan(TM) map -- creates a blueprint (or fingerprint) of your eye, allowing the iLASIK(TM) surgeon to custom-fit the iLASIK(TM) procedure for each of your eyes. -- Step Two: Two lasers are used in the iLASIK(TM) procedure. The first, ultra-fast laser creates a thin corneal flap, which is then folded back to allow the second laser to correct your vision based on the exact specification/measurements of your eye(s). The procedure takes just minutes. Patients experience a quick, virtually painless procedure with potential for 20/20 or better vision and unparalleled safety through reduced flap complications. -- Step Three: Final post-op visits are conducted and then you are free to resume your active lifestyle, with the potential of 20/20 or better vision.

Simply The Best: iLASIK(TM) Demonstrates Clinical Superiority From Start To Finish

More than a decade since FDA approval, LASIK remains not only the most common, but also the most clinically-studied elective surgical procedure to date. It was this very same clinical research that revealed the combination of technologies -- femtosecond and wavefront guided lasers, iris registration and 3-D mapping -- provided superior safety and better visual outcomes for patients than all previous LASIK techniques through reduced flap complications.

Clinical trials have shown more patients achieve 20/20 or better vision when two lasers are used, as in the iLASIK(TM) procedure, instead of the single-laser platform of previous LASIK techniques. Clinical studies using one of the components in the iLASIK(TM) procedure show that one year after iLASIK(TM) treatment*:

-- More than 95 percent of all clinical study participants could pass a driving test without glasses or contact lenses. -- Almost three-quarters of all participants could see 20/20 or better without glasses or contact lenses. -- Four times as many mild-to-moderately nearsighted participants were very satisfied with their night vision after treatment compared to their night vision before treatment with glasses or contacts. -- 98 percent of mild-to-moderately nearsighted patients could see 20/20 or better one year after treatment; 100 percent of mild-to-moderately nearsighted patients and more than 95 percent of patients with mixed astigmatism could pass a driving test without glasses or contact lenses.

The iLASIK(TM) procedure comprises the Advanced CustomVue(TM) excimer laser vision correction procedure using VISX(TM) Technology, corneal flap creation with the IntraLase(TM) FS (femtosecond) laser, and WaveScan(TM) mapping and guidance all from AMO.

About Advanced Medical Optics (AMO)

AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract/implant line include intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as ReZoom(R), Tecnis(R), Clariflex(R), Sensar(R), and Verisyse(R) IOLs, Sovereign(R), Sovereign(R) Compact and WhiteStar Signature(TM) phacoemulsification systems with WhiteStar(R) technology, Healon(R) viscoelastics, and the Baerveldt(R) glaucoma shunt. Products in the laser vision correction line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices, and excimer laser vision correction systems and treatment cards. AMO brands in the laser vision correction business include Star S4 IR(R), WaveScan Wavefront(R), Advanced CustomVue(TM), IntraLase(R) and IntraLasik(R). Products in the contact lens care line include disinfecting solutions, enzymatic cleaners and lens rewetting drops. Among the eye care product brands the company possesses are COMPLETE(R), COMPLETE(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, UltraCare(R), Ultrazyme(R), Total Care(TM) and blink(TM) branded products. AMO is based in Santa Ana, California, and employs approximately 4,200 worldwide. The company has operations in 24 countries and markets products in approximately 60 countries. For more information, visit the company's Website at http://www.amo-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements about AMO, including statements by Dr. Solomon and Mr. Bache and statements relating to expected product performance, trends and outcomes. All forward-looking statements in this press release are based on estimates and assumptions and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors including but not limited to market developments, clinical experience, variations in surgeon experience, and unexpected regulatory, quality or supply issues. Therefore, the reader is cautioned not to rely on these forward- looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2006 Form 10-K filed in March 2007 and third quarter Form 10-Q. Copies of press releases and additional information about AMO are available at http://www.amo-inc.com.

AMO, the AMO logo, iLASIK and the iLASIK logo are trademarks of Advanced Medical Optics, Inc. IntraLase is a trademark of AMO Development, LLC. VISX, Advanced CustomVue, CustomVue and WaveScan are trademarks of AMO Manufacturing USA, LLC.

*Data on file. AMO Manufacturing USA, LLC. Advanced CustomVue Procedure Clinical Trials; 2003, 2004, 2005, 2007.

Media Contacts Liana Miller / Kimberly Capwell eLuminatePR for AMO liana@eluminatepr.com (949) 276-8920 Steve Chesterman Manager, Corporate Communications steve.chesterman@amo-inc.com (714) 247-8711 Sheree Aronson Corporate Vice President, Investor sheree.aronson@amo-inc.com (714) 247-8290